Just months after facing a rejection in the US, the bispecific antibody odronextamab (Ordspono) has been approved by the European Commission for the treatment of two types of blood cancer in patients that have failed to respond to previous treatments.
AbbVie has announced that the Scottish Medicines Consortium (SMC) has approved Tepkinly (epcoritamab) for adults with diffuse large B-cell lymphoma (DLBCL) who have not responded to or have relapsed after at least two prior treatments.
Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.
The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.
Janssen, a Johnson & Johnson company, has announced that its bispecific antibody has been granted approval by the European Commission (EC) for use in certain patients with relapsed or refractory multiple myeloma (RRMM).
Loxo Oncology at Lilly, an R&D division of Eli Lilly and Co, and Merus, a Dutch clinical-stage oncology company, today announced a partnership to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.
Ichnos will launch with a portfolio of five clinical stage assets, a proprietary platform, as well as a biologics manufacturing facility and 350 employees.
I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.
ABL will use WuXi’s platforms in an extended agreement for the development and commercialization of its bispecific antibodies, using the recently launched WuXiBody platform.
AbbVie and Teneobio enter an agreement to develop and commercialize an immunotherapeutic for the treatment of multiple myeloma using the latter’s proprietary anti-CD3 platform.
A second single-use production line could offer commercial-scale capacity for bispecific antibodies but Glenmark says it would need to scale-up further to support more traditional biologics.
Ambrx says it will use its antibody platform in its collaboration with Zhejiang Hisun Pharmaceutical Company to develop and commercialise bispecifics for the treatment of cancer.
The evaluation of Genmab’s Duobody platform for the discovery and development of bispecific antibodies strengthens Eli Lilly’s biologics programme, the firm says.
OncoMed Pharmaceuticals announced last week that the US Patent and Trademark Office granted its first US patent for technology to identify mAbs (monoclonal antibodies).
